July 2007 Archives

Transcript provided by SeekingAlpha.com

"The first quarter was a very strong quarter for Perrigo. We had record sales, record operating income and all our new products are on-track to meet our goals for this year before we launch Omeprazole. We had strong positive cash flow from the operations in the first quarter, where we normally are users of cash. This is another very strong sign on the strength of our business.

Our Consumer Healthcare unit has $20 million in new business sales, which were a driver for this quarter as our team continues to rescue our customers, from our competitor's quality problems. This opportunity is worthening as our competitor has extended its time frame for returning to the OTC market.